key: cord-1019440-ir26fr91
authors: Ju, Chengsheng; Lau, Wallis C.Y.; Hayes, Joseph F.; Osborn, David; Man, Kenneth K.C.; Chan, Esther W.; Wong, Ian C.K.; Wei, Li
title: Impact of the COVID‐19 pandemic on use of anti‐dementia medications in 34 European and North American countries
date: 2021-10-14
journal: Alzheimers Dement (N Y)
DOI: 10.1002/trc2.12206
sha: fbbec8bfc1b2cd004a9684755988674346f967a1
doc_id: 1019440
cord_uid: ir26fr91

INTRODUCTION: The impact of the COVID‐19 pandemic on the global use of anti‐dementia medication is unknown. We aimed to determine the changes of anti‐dementia medication use in Europe (EU) and North America (NA) during the pandemic. METHODS: This is a cross‐sectional study using sales data of anti‐dementia medications in 2019 and 2020 from 34 EU and NA countries. The monthly uses of anti‐dementia medications from January through June in 2020 were compared to the corresponding months in 2019 for each country. RESULTS: In the pre‐pandemic period of January to March 2020, 70 out of 102 (3 months x 34 countries) measurements (68.6%) of monthly sales volume showed an increase. In contrast, 76.5% and 85.3% countries showed reduced sales in April and May 2020, respectively. DISCUSSION: These findings indicate changes in use of anti‐dementia medications during the pandemic. The delivery of pharmaceutical care for dementia patients may be heavily disrupted in certain countries.

The coronavirus disease 2019 (COVID-19) pandemic was expected to have a tremendous impact on patients with dementia. 1 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and dementia share common risk factors such as old age and comorbidities, and patients living with dementia are particularly vulnerable to the infection. 2, 3 The lockdown measures could have additional adverse disruptions to the diagnosis and delivery of care for dementia, and result in further strains on physical and mental well-being of the patients.

Anti-dementia medications are those used to control the progression of dementia. 4 sales data from a large number of countries and has been validated against external data sources. 6 The database has been used for epidemiological studies. 7 

There The sales of anti-dementia medication started to increase in June (20 out of the 34 countries, 58.8%; Figure 1B ).

In this study, we presented the monthly changes in anti-dementia medication sales over 6 months before and during the COVID-19 pandemic, while the reduction within the pandemic period may be due to reduced

Tackling challenges in care of Alzheimer's disease and other dementias amid the COVID-19 pandemic, now and in the future

Estimates of the severity of coronavirus disease 2019: a model-based analysis

Dementia prevention, intervention, and care: 2020 report of the Lancet Commission

Unburdening dementia -a basic social process grounded theory based on a primary care physician survey from 25 countries

Minimising long-term effect of COVID-19 in dementia care

ACTS: IQVIA Quality assurance

Consumption of oral antibiotic formulations for young children according to the WHO Access, Watch, Reserve (AWaRe) antibiotic groups: an analysis of sales data from 70 middle-income and high-income countries

Estimating global trends in total and childhood antibiotic consumption

World Population Prospectives: United Nations Population Divisions: United Nations Population Divisions

Trends in diagnosis and treatment for people with dementia in the UK from 2005 to 2015: a longitudinal retrospective cohort study

Pharmaceutical use and spending trend in Medicare beneficiaries with dementia

Short and long term impacts of COVID-19 on the pharmaceutical sector

European Commission: Guidelines on the optimal and rational supply of medicines to avoid shortages during the COVID-19 outbreak

Time-trend analysis of medicine sales and shortages during COVID-19 outbreak: data from community pharmacies

Impact of the COVID-19 pandemic on use of anti-dementia medications in 34 European and North American countries